|Podcasts|March 4, 2021

Episode 77: The Effects of AI on IP

Kevin Buckley, founder of Torrey Pines Law Group, and Neil Thompson, a patent agent with the firm, discuss IP strategy as it relates to pharma and artificial intelligence.

Kevin Buckley, founder of Torrey Pines Law Group, and Neil Thompson, a patent agent at the firm, talk about the increasing use of artificial intelligence in pharma and how that is affecting the realm of intellectual property.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.